Prateek Bhatia | Pediatric Hematology Genomics | Research Excellence Award

Dr. Prateek Bhatia | Pediatric Hematology Genomics | Research Excellence Award

PGIMER Chandigarh | India

Dr. Prateek Bhatia is an accomplished clinician-scientist and Principal Investigator known for his exceptional contributions to pediatric hematology-oncology and molecular diagnostics. With 1,244 citations from 1,134 documents, 143 published documents, and an h-index of 20, he has established a significant global research footprint in childhood leukemia, germline variant profiling, novel anemia syndromes, and pharmacogenetic responses to therapy. His education and advanced clinical training in pathology, hematology, and health management have enabled him to integrate laboratory excellence with patient-centered research. As an Additional Professor at a premier national institute, he leads numerous competitive, high-impact funded projects supported by ICMR, SERB-DST, CSIR, DST, and international grant bodies. His work focuses on defining genetic subtypes, clonal evolution, actionable molecular targets, and developing next-generation sequencing platforms and rapid diagnostic solutions tailored for resource-constrained settings. His research interests span acute lymphoblastic leukemia genomics, bone marrow failure disorders, iron-related anemias, epigenomic alterations, and point-of-care device development. Recognized as a Fellow of prestigious academies, he continues to advance precision hematology through innovative, clinically meaningful discoveries. His overarching mission is to enhance diagnostic accuracy, refine risk stratification, and improve outcomes for children with complex blood disorders through science-driven, compassionate care.

Profiles: Scopus | Orcid

Featured Publications

Neurological manifestations and clinical outcomes in pediatric Alexander disease: Single-center cohort and identification of novel GFAP variants. (2025). Brain and Development.

Clinicopathological and immunogenetic characterization in 8 patients with familial hemophagocytic lymphohistiocytosis type 2: A study from North India with literature review. (2025). Journal of Clinical Immunology.

Neutrophil lymphocyte ratio and clinical outcome in children admitted to PICU: A prospective observational study. (2025). Indian Journal of Pediatrics, 2 citations.

Altered expression of m6A-associated genes is linked with poor prognosis in pediatric acute myeloid leukemia patients. (2025). Biomolecules.

Skin biopsy revealing Langerhans cell histiocytosis during therapy for T-cell acute lymphoblastic leukemia: A fatal outcome. (2025). Journal of Cutaneous Pathology.

A comparative analysis of clinical utility of cytogenetics and copy-number–integrated risk stratification scores in a prospective cohort of pediatric B-cell acute lymphoblastic leukemia. (2025). Pediatric Blood and Cancer, 1 citation.

Satyamvada Maurya | Computational Biology | Best Researcher Award

Mrs. Satyamvada Maurya | Computational Biology | Best Researcher Award

ICAR-National Bureau of Fish Genetic Resources | India

Dr. Satyamvada Maurya is a bioinformatics researcher with extensive experience in genomics, computational biology, and drug discovery. She holds a Ph.D. in Bioinformatics, focusing on the design and development of novel anti-tuberculosis agents through computational approaches. Her academic foundation includes a Master’s in Bioinformatics and a Bachelor’s in Biotechnology, which laid the groundwork for her multidisciplinary research. She has worked as a Project Assistant and Young Professional in premier Indian research institutes, contributing to projects in genome analysis, database development, SNP characterization, and functional genomics of aquatic organisms, particularly Clarias magur. Her research interests span next-generation sequencing, genome analysis, protein structure-function prediction, drug design, homology modeling, phylogenetic analysis, and database creation for biological resources. She has authored multiple research articles, book chapters, training manuals, and popular science articles, accumulating 27 citations with an h-index of 3 and i10-index of 1, reflecting the impact of her work. She has received awards including the TEQIP fellowship and best presentation accolades at national and international conferences. Dr. Maurya is committed to advancing bioinformatics applications in both healthcare and aquaculture, bridging computational tools with experimental biology to address complex biological challenges. Her work continues to contribute to the development of innovative solutions in genomics and drug discovery.

Profile: Google Scholar

Featured Publications

Verma, S., Maurya, R., & Maurya, S. (2016). Prediction of gene action and combining ability for yield and quality traits in F1 and F2 generations of wheat (Triticum aestivum L.). Tropical Plant Research, 3(2), 449–459.

Maurya, S., Jain, A., Singh, V., Haque, S., & Mishra, B. N. (2023). Evaluation of Saraca asoca for its anti-tubercular potential via molecular docking and molecular dynamics simulation studies. ChemistrySelect, 8(12), e202204899.

Maurya, S., Alhazmi, A., Vidyarthi, A. S., Jain, A., Singh, V., Khan, F., Haque, S., & Mishra, B. N. (2022). In-silico study reveals potential antitubercular drug targets unique to Mycobacterium tuberculosis H37Rv. Minerva Biotechnology & Biomolecular Research, 34(2), 71–79.

Maurya, S., Kumar, M. S., Kumar, R., & Kushwaha, B. (2024). Role of machine learning and artificial intelligence in transforming aquaculture and fisheries sector. Indian Farming, 74(8), 24–27.

Maurya, S., Jain, A., Rehman, M. T., Hakamy, A., Bantun, F., AlAjmi, M. F., Singh, V., … Mishra, B. N. (2023). In silico identification of novel derivatives of rifampicin targeting Ribonuclease VapC2 of M. tuberculosis H37Rv: Rifampicin derivatives target VapC2 of Mtb H37Rv. Molecules, 28(4), 1652.